Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02216409 | Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody | PHASE1 | COMPLETED | 88 | — | — | Aug 1, 2014 | Dec 1, 2018 | Feb 5, 2019 | 6 | United States |
The CTCAE criteria will be used to assess adverse events on this trial.
| Arm | Type | Description |
|---|---|---|
| Treatment (Hu5F9-G4) | EXPERIMENTAL | Hu5F9-G4 monotherapy |
| Name | Type | Description |
|---|---|---|
| Hu5F9-G4 | DRUG | - |
Inclusion Criteria: Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment. Adequate hematologic status Adeq...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |